Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Taps Source BioScience for Cancer PGx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Source BioScience said today that it will provide drugmaker AstraZeneca with a companion diagnostic testing service for lung cancer patients in the UK.

The service agreement with AstraZeneca will enable doctors at the National Health Service to identify which lung cancer patients have certain genetic mutations in their tumors that may make them sensitive to tyrosine kinase inhibitor therapies, which in turn may help guide doctors' treatment decisions.

Source BioScience will conduct full pathology reviews, genetic testing, and diagnostic analysis at its labs in Nottingham and return the reports within five working days.

"If we are able to provide better diagnostics information for clinicians, this will help ensure that treatment pathways are managed more effectively, positively impacting the clinical outcome and cost effectiveness of therapy," Source BioScience Managing Director Nick Ash said in a statement. "Increasing demand for targeted therapies to improve treatment success and reduce costs is generating demand for companion diagnostics to accompany those therapies," Ash added.

The service will be funded by AstraZeneca, but specific financial terms of the agreement were not released.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.